乳腺癌预后和预测测试的组织系统生物学-猫眼课题宝

乳腺癌预后和预测测试的组织系统生物学

批准号：

7744772

负责人：

Rebecca Critchley-Thorne

金额：

$14.73万

依托单位：

CERNOSTICS, INC.

依托单位国家：

美国

项目类别：

财政年份：

2009

资助国家：

美国

项目状态：

已结题

起止时间：

2009-09-28 至 2012-08-31

来源：

https://reporter.nih.gov/project-details/7744772

关键词：

Acute Automobile Driving Award Biological Markers Breast Cancer Treatment Cancer Patient Cessation of life Clinic Clinical Collaborations Color Complex Computer software Coupled Data Decision Making Development Diagnosis Diagnostic Diagnostic tests Disease Management Fluorescence Formalin Growth Image Image Analysis Immune system Immunofluorescence Immunologic In Vitro Individual Malignant Neoplasms Mammary Neoplasms Marketing Measurement Measures Methods Monitor Outcome Paraffin Embedding Pathology Patients Phase Phase I Clinical Trials Prediction of Response to Therapy Process Production Prospective Studies Proteins Recurrence Research Retrospective Studies Risk Sensitivity and Specificity Slide Solutions Staining method Stains Survival Rate System Systems Biology Testing Tissue Microarray Tissues Tumor Tissue Tumor-Associated Process Woman aggressive therapy base cancer therapy cancer type chemotherapy cohort digital imaging fluorescence imaging high risk immune function improved indexing malignant breast neoplasm outcome forecast prognostic public health relevance response technological innovation tool tumor tumor progression

项目摘要

项目成果

Rebecca Critchley-Thorne的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

DESCRIPTION (provided by applicant): Breast cancer is the most frequently diagnosed type of cancer in women, with 1.3 million new diagnoses and 465,000 deaths annually worldwide. There is an acute need for improved prognostic and predictive tools to aid individualized treatment for breast cancer. Tests are specifically required to identify high risk patients requiring aggressive therapy and monitoring, low risk patients who may be spared unnecessary chemotherapy, and to select specific therapies to which individuals are likely to respond. Such tests are critical to improve disease management and survival rates for breast cancer patients. The long term objective of the project is to develop and commercialize a tissue-based multiplexed immunofluorescence biomarker test for breast cancer to predict clinical outcome and responses to therapies with higher sensitivity and specificity than current diagnostic tools. An optimal panel of biomarkers will be determined using the Tissue Systeumors that can be reduced to decision "indices" with the aid of classifiers constructed from retrospective studies. In Phase I the project specifically aims to retrospectively evaluate a panel of 24 prognostic and predictive functional biomarkers by multiplexed immunofluorescence staining on tissue microarrays of breast tumor tissues from patients with good outcome and patients with poor outcome. Precise intracellular measurements of the biomarkers will be made by quantitative analysis of images generated by fluorescence digital imaging pathology. The biomarker measurements will be correlated with clinical and pathological data to determine an optimal panel of functional biomarkers. Classifier software will be built using the optimal biomarker panel to predict recurrence risk, survival and clinical outcome. The classifier will be the critical solution to convert the complex biomarker data to meaningful indices for prognostic purposes. In the Phase II of the project the utility, speciest as an addition to thecurrent IHC measurements performed at diagnosis tumor tissue sections. Successful development of the test will enable more accurate prognoses and predictions for individualized decision-making and improved disease management for breast cancer. PUBLIC HEALTH RELEVANCE: There is an acute need for improved prognostic and predictive tests to aid individualized management for breast cancer. The proposed research aims to develop a Tissue Systems Biology (CSBTM) profiling test that measures a combination of the key functions of tumors including, the immune system, that control tumor spread and the responses of tumors to cancer therapies. The test will enable more accurate prognoses and predictions of responses to therapies for individual breast cancer patients to improve management of the disease.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文

Stratification of Cancer Risk in Patients with Non-Dysplastic Barrett's Esophagus using TissueCypher: The SCRiBE study

批准号：

10561001
项目类别：
资助金额：

$59.27万
财政年份：

2023
负责人：

Rebecca Critchley-Thorne
依托单位：

BAYLOR RESEARCH INSTITUTE

TissueCypher Testing for Risk Assessment in Barretts Esophagus

批准号：

8980580
项目类别：
资助金额：

$62.49万
财政年份：

2015
负责人：

Rebecca Critchley-Thorne
依托单位：

CERNOSTICS, INC.

海外基金